Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM): How Practice is Changing

Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM) How Practice is Changing Review Abstract The integration of continuous glucose monitoring technology into diabetes management has significantly reshaped clinical practice over the past decade. Continuous glucose monitoring systems provide real time, dynamic assessment of interstitial glucose

Type 2 Diabetes Mellitus: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention

Type 2 Diabetes Mellitus as a Multifactorial Cardiometabolic Disease: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention Narrative Review Abstract Type 2 diabetes mellitus (T2DM) is a progressive, heterogeneous, multi-organ metabolic disease characterized by chronic hyperglycemia arising from inadequate insulin secretion relative to metabolic demand, usually

Obesity as Chronic Disease: Building a Follow-up Model Like HTN/A1c

Obesity as Chronic Disease Building a Follow-up Model Like HTNA1c   Abstract Obesity is increasingly recognized as a chronic, relapsing, multifactorial disease that requires long term clinical management rather than episodic intervention. Its pathophysiology involves complex interactions among genetic predisposition, neuroendocrine regulation, metabolic adaptation, environmental

Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility

Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility: Mechanisms, Evidence, and Clinical Implications Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for the treatment of type 2 diabetes mellitus and obesity. Increasingly, reports suggest a possible association between GLP-1 RA use and

The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?

The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?   Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting

Dementia Risk Increase In Diabetic Patients With Poor Glycemic Control

Dementia Risk Increase In Diabetic Patients With Poor Glycemic Control Overview This study investigated the association between glycemic variability and dementia risk among 171,964 individuals with type 2 diabetes. Despite optimal glycosylated hemoglobin A1c (HbA1c) levels, variability in HbA1c over the long term was found to increase the hazard of dementia. The

Latest Research Exploring Metformin Connection To Breast Cancer

Latest Research Exploring Metformin Connection To Breast Cancer Overview This study aimed to investigate the relationship between metformin and other antidiabetic medications and the incidence of breast cancer in two large prospective cohort studies. It included 185,181 women from the Nurses' Health Study (NHS; 1994–2016) and NHSII (1995–2017). Information on type 2

Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM): How Practice is Changing